PT  - JOURNAL ARTICLE
AU  - Moreau, Allison L.
AU  - Voss, Michaela
AU  - Hansen, Isabella
AU  - Paul, Sarah E.
AU  - Barch, Deanna M.
AU  - Rogers, Cynthia E.
AU  - Bogdan, Ryan
TI  - Prenatal Selective Serotonin Reuptake Inhibitor Exposure, Depression and Brain Morphology in Middle Childhood: Results from the ABCD Study
AID  - 10.1101/2021.09.01.21262980
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.01.21262980
4099  - http://medrxiv.org/content/early/2021/09/07/2021.09.01.21262980.short
4100  - http://medrxiv.org/content/early/2021/09/07/2021.09.01.21262980.full
AB  - Objective Prenatal selective serotonin reuptake inhibitor (SSRI) exposure has been inconsistently linked to depression. Potential neural intermediaries remain understudied. We examined whether prenatal SSRI exposure is associated with depressive symptoms and brain structure during middle childhood.Methods Prenatal SSRI exposure (retrospective caregiver-report), depressive symptoms (caregiver-reported Child Behavior Checklist) and brain structure (MRI-derived subcortical volume; cortical thickness and surface area) were assessed in children (analytic ns=5,420-7,528; 235 with prenatal SSRI exposure; 9-10 years old) who completed the baseline session of the Adolescent Brain and Cognitive DevelopmentSM Study. Covariates included familial (e.g., 1st degree relative depression density), pregnancy (e.g., planned pregnancy), and child (e.g., birthweight) variables. Matrix spectral decomposition was used to address multiple testing.Results There was no evidence that prenatal SSRI exposure was associated with child depression after accounting for recent maternal depressive symptoms. Prenatal SSRI exposure was associated with greater left superior parietal surface area (b=145.3 mm2, p=0.00038) and lateral occipital cortical thickness (b=0.0272 mm, p=0.0000079), neither of which was associated with depressive symptoms.Conclusions Our findings, combined with adverse associations of prenatal exposure to maternal depression and the utility of SSRIs for treating depression, suggest that risk for child depression during middle childhood should not discourage SSRI use during pregnancy. It will be important for future work to examine associations between prenatal SSRI exposure and depression through young adulthood, when risk for depression increases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementData for this study were provided by the Adolescent Brain Cognitive Development Study℠ (ABCD Study), which was funded by awards U01DA041022, U01DA041025, U01DA041028, U01DA041048, U01DA041089, U01DA041093, U01DA041106, U01DA041117, U01DA041120, U01DA041134, U01DA041148, U01DA041156, U01DA041174, U24DA041123, and U24DA041147 from the NIH and additional federal partners (https://abcdstudy.org/federal-partners.html). Authors received funding support from NIH: Dr. Rogers (R01-DA046224, R34-DA050272, R01-MH121877, R01-MH113570), Dr. Barch (R01-MH113883, R01-MH066031, U01-MH109589, U01-A005020803, R01-MH090786), Dr. Bogdan (R01-AG045231, R01-HD083614, R01-AG052564, R21-AA027827, R01-DA046224). The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All parents provided written informed consent after receiving a complete description of the study, and all children provided verbal assent to a research protocol approved by the institutional review board at each ABCD data collection site (n=22) throughout the United States. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data in these analyses came from the publicly available Adolescent Brain and Cognitive Development (ABCD) Study dataset (release version 2.0.1) housed on the National Institute of Mental Health's Data Archive (NDA). https://nda.nih.gov/